As of 2025-06-22, the EV/EBITDA ratio of Arcturus Therapeutics Holdings Inc (ARCT) is -1.67. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ARCT's latest enterprise value is 131.36 mil USD. ARCT's TTM EBITDA according to its financial statements is -78.64 mil USD. Dividing these 2 quantities gives us the above ARCT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.9x - 11.9x | 11.9x |
| Forward P/E multiples | 11.9x - 20.2x | 16.0x |
| Fair Price | (27.06) - (27.06) | (33.08) |
| Upside | -320.2% - -320.2% | -369.1% |
| Date | EV/EBITDA |
| 2025-06-10 | -1.88 |
| 2025-06-09 | -1.76 |
| 2025-06-06 | -1.84 |
| 2025-06-05 | -1.54 |
| 2025-06-04 | -1.66 |
| 2025-06-03 | -1.92 |
| 2025-06-02 | -1.85 |
| 2025-05-30 | -1.75 |
| 2025-05-29 | -1.82 |
| 2025-05-28 | -1.51 |
| 2025-05-27 | -1.58 |
| 2025-05-23 | -1.64 |
| 2025-05-22 | -1.85 |
| 2025-05-21 | -1.62 |
| 2025-05-20 | -1.81 |
| 2025-05-19 | -1.57 |
| 2025-05-16 | -1.45 |
| 2025-05-15 | -1.45 |
| 2025-05-14 | -1.17 |
| 2025-05-13 | -1.52 |
| 2025-05-12 | -1.43 |
| 2025-05-09 | -1.22 |
| 2025-05-08 | -1.36 |
| 2025-05-07 | -1.21 |
| 2025-05-06 | -1.31 |
| 2025-05-05 | -1.54 |
| 2025-05-02 | -1.86 |
| 2025-05-01 | -1.74 |
| 2025-04-30 | -1.85 |
| 2025-04-29 | -1.85 |
| 2025-04-28 | -1.85 |
| 2025-04-25 | -1.88 |
| 2025-04-24 | -1.88 |
| 2025-04-23 | -1.79 |
| 2025-04-22 | -1.63 |
| 2025-04-21 | -1.23 |
| 2025-04-17 | -1.06 |
| 2025-04-16 | -0.98 |
| 2025-04-15 | -1.08 |
| 2025-04-14 | -0.94 |
| 2025-04-11 | -0.78 |
| 2025-04-10 | -0.66 |
| 2025-04-09 | -0.82 |
| 2025-04-08 | -0.50 |
| 2025-04-07 | -0.57 |
| 2025-04-04 | -0.57 |
| 2025-04-03 | -0.70 |
| 2025-04-02 | -0.95 |
| 2025-04-01 | -0.68 |
| 2025-03-31 | -1.08 |